- A three-injection series of GELSYN-3 (0.8% highly purified, hyaluronic acid of biofermentative origin) or Synvisc® (0.8% hylan G-F20)
- Patients (n=380) were observed for a period of 26 weeks
- Primary Outcome Measure: WOMAC pain score at 26 weeks
Effective Viscosupplement Performance
for Improved Outcomes4*
GELSYN-3 performs as well as Synvisc in terms of effectiveness and safety, providing patients with long-lasting, clinically relevant pain relief.
*Sinovial® is branded as GELSYN-3 for the US Market.